Global Genomics Group (G3) has entered into a research collaboration with Sanofi to identify new signaling pathways and targets involved in coronary artery disease. G3 will receive undisclosed payments from Sanofi under the collaboration.   The companies will use G3’s platform with data from its G3LOBAL Database to further decipher the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with these signaling pathways...